
Eli Lilly’s heart drug underwhelms with REWIND trial
pharmafile | June 11, 2019 | News story | Manufacturing and Production | Eli Lilly, Trulicity, pharma
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.
The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.
While Lilly’s drug was effective in reducing major cardiovascular events the drug failed to meet the expectations of investors. According to MarketWatch Cowen analysts said investors had expected at least 20% risk reduction.
Shares in the Indianapolis-based firm fell by 2.4% in premarket trading.
Louis Goss
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …






